ClinicalTrials.gg
WithdrawnNCT01260090Updated Apr 27, 2023

Vagus Nerve Stimulation to Augment Recovery From Minimally Conscious or Persistently Vegetative States After Traumatic Brain Injury

A Phase 2/3 interventional study of Vagus nerve stimulation; and No stimulation in Minimally Conscious States Due to Traumatic Brain Injury and Persistently Vegetative States Due to Traumatic Brain Injury, sponsored by VA New York Harbor Healthcare System. Withdrawn at 1 site in United States. Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2023-04-27.

Sponsored by VA New York Harbor Healthcare System · Phase 2/3, Interventional, and Treatment

Why this study was withdrawn
When Hurricane Sandy hit the area, the funding was pulled.
Phase
Phase 2/3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Study summary

Traumatic brain injury has a high morbidity and mortality in both civilian and military populations. Blast and other mechanisms of traumatic brain injury damage the brain by causing neurons to disconnect and atrophy. Such traumatic axonal injury can lead to persistently vegetative and minimally conscious states, for which extremely limited treatment options exist, including physical, occupational, speech and cognitive therapies.

More than 50,000 patients have received vagus nerve stimulation for epilepsy and depression. In addition to decreased seizure frequency and severity, patients report enhanced mood, reduced daytime sleepiness independent of seizure control, increased slow wave sleep, and improved cognition, memory, and quality of life.

The purpose of this study is to demonstrate objective improvement in clinical outcome by placement of a vagus nerve stimulator in patients who are recovering from severe traumatic brain injury. Our hypothesis is that stimulation of the vagus nerve results in increased cerebral blood flow and metabolism in the forebrain, thalamus and reticular formation, which promotes arousal and improved consciousness, thereby improving outcome after traumatic brain injury resulting in minimally conscious or persistent vegetative states. If this study demonstrates that vagus nerve stimulation can safely and positively impact outcome, then a larger randomized prospective crossover trial will be proposed.

The investigators will achieve this objective by evaluating whether vagus nerve stimulation impacts clinical recovery from minimally conscious or persistent vegetative states caused by traumatic brain injury as assessed by the FIM™ instrument and Functional Assessment Measure (FIM+FAM) as well as the JFK Coma Recovery Scale Score. The investigators will also evaluate whether vagus nerve stimulation alters resting and activational functional MRI.

Twelve patients will be enrolled in this initial crossover pilot study. These patients will have sustained a severe traumatic brain injury (Disability Rating Scale score of 22 to 29) more than twelve months from starting the study, and have no other concurrent active severe medical problems. Baseline EEG and magnetic resonance imaging (MRI) will be performed prior to left vagus nerve stimulation implantation. Patients will be randomized to alternating three month periods with the device on or off. Outcomes will be assessed at three month intervals with the FIM™ instrument and Functional Assessment Measure (FIM+FAM) and JFK Coma Recovery Scale by a neuropsychologist blinded to the status of the device. Outcomes will also be assessed using quantitative eye movement tracking and functional magnetic resonance imaging. Patients will cross over every 3 months and be followed for at least 18 months.

02

Conditions studied

  • Minimally Conscious States Due to Traumatic Brain Injury
  • Persistently Vegetative States Due to Traumatic Brain Injury

Keywords

  • Minimally conscious states
  • Persistently vegetative states
  • Traumatic brain injury
03

In context

Persistent Vegetative State

88 studies on the registry are indexed under Persistent Vegetative State; 20 are open to participants now.

Browse Persistent Vegetative State studies →

Lead sponsor

VA New York Harbor Healthcare System is the lead sponsor of 15 studies on the registry; none are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 60
  • greater than 12 months from a moderate to severe traumatic brain injury
  • Disability Rating Scale score of 18 to 29
  • with or without concurrent seizure activity
  • Eligible for care in the VA system

Exclusion criteria

Exclusion Criteria:

  • Anoxic mechanism of brain injury (eg prolonged arrest)
  • Untreated hydrocephalus
  • Elevated intracranial pressure
  • Systemic issues precluding surgery or 18 months survival
  • Traumatic injuries precluding surgery or 18 months survival
  • Retained shrapnel or other metal contraindicating MRI
  • Prior vagotomy
  • Sleep apnea
  • Myocardial infarction, arrhythmia
  • History of cardiac conduction abnormality
  • Pregnancy or intent to become pregnant
  • Pre-existing CNS disease
05

Study design

Phase
Phase 2 / Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Triple (Participant, Care provider, Outcomes assessor)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Vagus Nerve Stimulation

    Name of the Device: We will use the PMA approved version of the NCP System, including the NCP Generator (model 103), NCP Programming Wand (model 201), NCP Programming Software (model 250v7.1), NCP Lead (model 304), NCP Tunneling Tool (model 402) and the Patient Magnet (model 220). FDA Facility Registration Number: 1644487

    Device: Vagus nerve stimulation;

  • Sham comparator
    No Stimulation

    Device: No stimulation

Interventions

  • DeviceVagus nerve stimulation;

    Name of the Device: We will use the PMA approved version of the NCP System, including the NCP Generator (model 103), NCP Programming Wand (model 201), NCP Programming Software (model 250v7.1), NCP Lead (model 304), NCP Tunneling Tool (model 402) and the Patient Magnet (model 220). FDA Facility Registration Number: 1644487

  • DeviceNo stimulation

    Vagus nerve stimulation

06

What researchers measure

Primary outcomes

  1. JFK Coma Recovery Scale

    Time frame: every 3 months for 18 months

Secondary outcomes

  1. FIM plus FAM

    Time frame: every 3 months for 18 months

  2. functional MRI

    Time frame: every 3 months for 18 months

07

Study locations

1 site
  • Manhattan Va NYHHCS
    New York, New York 10010, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Jan 2011 to primary completion in Jul 2013, 30 months.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 14, 2010
First posted
Dec 15, 2010
StartActual
Jan 2011
Primary completionActual
Jul 2013
CompletionActual
Oct 2013
Last update
Apr 27, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 27, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT01260090
Lead sponsor
VA New York Harbor Healthcare System
Responsible party
Uzma Samadani (Neurosurgeon, VA New York Harbor Healthcare System) — Principal investigator
First posted
Dec 15, 2010
Start date
Jan 2011
Primary completion
Jul 2013
Completion
Oct 2013
Last update
Apr 27, 2023
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Apr 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion